Salobir Barbara, Sabovic Miso, Hojnik Maja, Cucnik Sasa, Kveder Tanja
Department of Vascular Diseases, University Medical Centre, 1000 Ljubljana, Slovenia.
Immunobiology. 2007;212(3):193-9. doi: 10.1016/j.imbio.2007.01.001. Epub 2007 Feb 1.
Antiphospholipid autoantibodies particularly antibodies against beta2-glycoprotein I (anti-beta2GPI) are casually associated with thromboses in patients with autoimmune diseases. However, their exact prevalence and role in the pathogenesis of thromboses in the absence of autoimmune disease is still inconclusive. They might be particularly important when other risk factors of thrombosis are absent. We investigated antiphospholipid antibodies in 68 young women (aged <45yr at onset of the event, without autoimmune disease and with an otherwise low risk of thrombosis) in the stable period following myocardial infarction (MI), lacunar cerebral infarction (LACI) or deep vein thrombosis (DVT) and in 37 healthy age-matched controls. Patients had increased IgM anti-beta2GPI compared to controls (36.0, 11.5-49.5 vs. 17.50, 3.50-30.0 arbitrary units (AU), p<0.001), whereas no difference was obtained in other measured antibodies (anticardiolipin and antiphosphatidylserine (aPS) antibodies of IgG and IgM). IgM anti-beta2GPI positively correlated with some markers of increased coagulation potential and negatively with BMI (r=-039, p<0.005) and other parameters of the metabolic syndrome. In conclusion, we found that levels of IgM anti-beta2GPI are increased in young women suffering arterial or venous thromboses in the absence of other known autoimmune diseases and also in the absence of pronounced classical risk factors. We found that IgM anti-beta2GPI positively correlated with some markers of increased coagulation potential and negatively with parameters of the metabolic syndrome. Thus, it appears that elevated levels of IgM anti-beta2GPI are linked to thrombotic disorders in young women (without autoimmune disease) particularly when classical risk factors or the metabolic syndrome are absent.
抗磷脂自身抗体，尤其是抗β2糖蛋白I抗体（抗β2GPI）与自身免疫性疾病患者的血栓形成存在偶然关联。然而，在无自身免疫性疾病的情况下，它们在血栓形成发病机制中的确切患病率和作用仍无定论。当不存在其他血栓形成风险因素时，它们可能尤为重要。我们调查了68名年轻女性（事件发生时年龄<45岁，无自身免疫性疾病且其他方面血栓形成风险较低）在心肌梗死（MI）、腔隙性脑梗死（LACI）或深静脉血栓形成（DVT）稳定期以及37名年龄匹配的健康对照者体内的抗磷脂抗体。与对照组相比，患者的IgM抗β2GPI升高（分别为36.0，11.5 - 49.5与17.50，3.50 - 30.0任意单位（AU），p<0.001），而在其他检测抗体（IgG和IgM的抗心磷脂和抗磷脂酰丝氨酸（aPS）抗体）方面未发现差异。IgM抗β2GPI与一些凝血潜能增加的标志物呈正相关，与体重指数（BMI）呈负相关（r = -0.39，p<0.005）以及代谢综合征的其他参数。总之，我们发现，在无其他已知自身免疫性疾病且无明显经典风险因素的年轻女性中，患动脉或静脉血栓形成时IgM抗β2GPI水平升高。我们发现IgM抗β2GPI与一些凝血潜能增加的标志物呈正相关，与代谢综合征的参数呈负相关。因此，似乎IgM抗β2GPI水平升高与年轻女性（无自身免疫性疾病）的血栓性疾病有关，尤其是在不存在经典风险因素或代谢综合征时。
